Analysts Set Enfusion, Inc. (NYSE:ENFN) Target Price at $10.50

Shares of Enfusion, Inc. (NYSE:ENFN) have been given a consensus recommendation of “Hold” by the six ratings firms that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $10.50.

Several analysts have issued reports on the stock. Piper Sandler raised their price target on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. William Blair reiterated a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. Finally, Stifel Nicolaus lifted their target price on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th.

Enfusion Price Performance

NYSE ENFN opened at $11.06 on Thursday. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of 276.57, a P/E/G ratio of 1.83 and a beta of 0.96. The company’s fifty day moving average is $10.70 and its two-hundred day moving average is $9.54. Enfusion has a 52-week low of $7.83 and a 52-week high of $11.38.

Insider Buying and Selling

In related news, CEO Oleg Movchan sold 2,771 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total transaction of $28,070.23. Following the completion of the sale, the chief executive officer now directly owns 526,702 shares of the company’s stock, valued at $5,335,491.26. The trade was a 0.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Bradley Herring sold 24,443 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $10.61, for a total transaction of $259,340.23. Following the sale, the chief financial officer now directly owns 270,503 shares of the company’s stock, valued at approximately $2,870,036.83. This trade represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,367 shares of company stock valued at $591,335 over the last ninety days. Insiders own 36.44% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ENFN. TenCore Partners LP acquired a new position in Enfusion during the third quarter valued at approximately $3,938,000. New York State Common Retirement Fund grew its holdings in Enfusion by 23.8% during the fourth quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company’s stock valued at $19,848,000 after purchasing an additional 370,498 shares during the period. Arrowstreet Capital Limited Partnership acquired a new position in Enfusion during the fourth quarter valued at approximately $2,358,000. Impax Asset Management Group plc grew its holdings in Enfusion by 31.5% during the fourth quarter. Impax Asset Management Group plc now owns 890,000 shares of the company’s stock valued at $9,167,000 after purchasing an additional 213,052 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Enfusion by 57.5% during the second quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock valued at $4,466,000 after purchasing an additional 191,436 shares during the period. Institutional investors and hedge funds own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.